Celgene Co. (CELG) Shares Bought by Massey Quick Simon & CO. LLC

Massey Quick Simon & CO. LLC boosted its stake in shares of Celgene Co. (NASDAQ:CELG) by 549.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,202 shares of the biopharmaceutical company’s stock after purchasing an additional 2,709 shares during the quarter. Massey Quick Simon & CO. LLC’s holdings in Celgene were worth $467,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Thompson Davis & CO. Inc. lifted its holdings in shares of Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI lifted its holdings in shares of Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares in the last quarter. Guidant Wealth Advisors acquired a new stake in shares of Celgene during the third quarter worth $119,000. Motco lifted its holdings in shares of Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares in the last quarter. Finally, Penserra Capital Management LLC acquired a new stake in shares of Celgene during the second quarter worth $129,000. 79.74% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts recently commented on the company. Mizuho set a $128.00 price target on Celgene and gave the company a “buy” rating in a research note on Tuesday, December 26th. William Blair reaffirmed an “outperform” rating on shares of Celgene in a research note on Friday, October 20th. BidaskClub raised Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Citigroup reaffirmed a “hold” rating on shares of Celgene in a research note on Friday, December 22nd. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $156.00 price target on shares of Celgene in a research note on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have assigned a buy rating to the company. Celgene currently has an average rating of “Buy” and an average target price of $131.18.

Shares of Celgene Co. (NASDAQ CELG) opened at $106.00 on Friday. The firm has a market capitalization of $83,460.00, a PE ratio of 25.00, a PEG ratio of 0.68 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Co. has a twelve month low of $94.55 and a twelve month high of $147.17.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 43.32% and a net margin of 30.06%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.58 earnings per share. research analysts anticipate that Celgene Co. will post 6.68 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2018/01/13/celgene-co-celg-shares-bought-by-massey-quick-simon-co-llc.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

What are top analysts saying about Celgene? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit